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Edited by Ivan SadowskiAbstract HDAC inhibitors are promising anticancer agents
that induce cell cycle arrest and apoptosis. However, the role
of HDACs in cancer progression, such as angiogenesis and
metastasis, remains largely unexplored. Among various HDAC
inhibitors, we demonstrate that TSA and SAHA upregulated
the expression of angiostatic ADAMTS1 in A549 cells. HDAC6
inhibitor tubacin, and knockdown of HDAC6, also lead to
ADAMTS1 upregulation. By reporter, DAPA, and ChIP as-
says, the proximal GC boxes were demonstrated to be essential
for ADAMTS1 induction. Decreased binding of SP1 and
HDAC6 to the ADAMTS1 promoter after TSA treatment was
also seen. These data suggest the involvement of HDAC6 and
SP1 in the HDACi-induced expression of angiostatic ADAM-
TS1.
Crown Copyright  2008 Published by Elsevier B.V. on behalf of
the Federation of European Biochemical Societies. All rights
reserved.
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Removing the acetyl group added by histone acetyltransfer-
ase (HAT) has been identiﬁed as the ﬁrst step in gene silencing
[1]. Abnormal histone deacetylation not only results in gene
silencing but also reduces DNA repair [2], thereby accelerating
cancer initiation and progression. Histone deacetylases
(HDACs), which are responsible for removing acetyl groups
from histones, were upregulated in tumors derived from sev-
eral origins [3]. Moreover, global hypoacetylation of histone
H4 represents a hallmark of human tumors [4]. Thus, HDACs
have become the emerging target for cancer therapy, and small
molecule inhibitors of HDACs have shown promising clinical
applications as antitumor agents [5]. HDAC inhibitors
(HDACi) cause histone hyperacetylation and reactivation of
tumour-suppressor genes. For example, HDACi have been
shown to induce cyclin-dependent kinase (CDK) inhibitors
such as p21 [6], and to activate the death-receptor-mediated
extrinsic apoptotic pathways [7,8]. Although these eﬀects were
reported to contribute to their antitumor activity, the eﬀects of
HDACi on cancer progression, such as angiogenesis and
metastasis, are largely unexplored.Abbreviations: HDAC, histone deacetylase; ADAMTS, a disintegrin
and metalloproteinase with thrombospondin motif
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doi:10.1016/j.febslet.2008.10.048ADAMTS1 is an extracellular metalloproteinase known to
participate in various biological processes that includes inﬂam-
mation, angiogenesis, and development of the urogenital sys-
tem [9]. It belongs to the ADAMTS (a disintegrin and
metalloproteinase with thrombospondin motif) protein family
[10,11], and contains the propeptide region, a metalloprotein-
ase domain, two disintegrin loops and three C-terminal throm-
bospondin type 1(TS) motifs [12]. ADAMTS1 cleavages
aggrecan, an extracellular matrix found mostly in cartilage,
and versican, a widely distributed extracellular matrix compo-
nent [13]. Although metalloproteinase was generally thought
to promote the invasion of tumor cells, ADAMTS1 is reported
to be a potent inhibitor of angiogenesis by sequestration of
VEGF165 and release of angioinhibitory thrombospondin 1/
2 [9,14–16]. Lower expression of ADAMTS1 is observed in
non-small-cell lung cancer (NSCLC) [17]. According to its
angioinhibitory ability and silencing in NSCLC [17], it is pos-
sible that ADAMTS1 may serve as a tumor suppressor in
NSCLC. Therefore, uncovering the mechanism of its silencing
may facilitate the development of NSCLC therapy.
In this study, we found broad spectrum HDACi, TSA and
SAHA [3] were capable of inducing ADAMTS1 expression.
A549 cells with reduced expression of HDAC6, a member of
class IIb HDAC, showed higher expression of ADAMTS1.
A speciﬁc inhibitor of HDAC6, tubacin [18], also induced
ADAMTS1 expression. By reporter, DAPA and ChIP assays,
the proximal GC boxes are demonstrated to be essential for
ADAMTS1 induction, and decreased binding of SP1 and
HDAC6 to ADAMTS1 promoter after TSA treatment was
also seen. These data suggest that HDAC6 and SP1 are in-
volved in the HDACi-induced expression of angiostatic
ADAMTS1.2. Materials and methods
2.1. Cell culture and reagents
A549 human lung carcinoma cells from ATCC were cultured in
DMEM supplemented with 10% fetal bovine serum. A549 variants
with intact HDAC6 expression (pSuper) or reduced HDAC6 expres-
sion by RNA interference (HD6KD) were kindly provided by Dr.
Yao (Department of Pharmacology and Cancer Biology, Duke Uni-
versity) [19]. Tubacin and niltubacin were provided by Dr. Ralph Maz-
itschek, who are supported by ICG (Initiative for Chemical Genetics –
National Cancer Institute) [18]. The ADAMTS1 promoter constructs
1186, 375, 151 bp and GC boxes mutants were generous gifts
from Dr. JoAnne S. Richards [20].
2.2. Western blot analysis
Following treatment with HDAC inhibitors, total cell lysates or nu-
clear extracts were prepared and subjected to SDS–PAGE using ade-
quate percentage polyacrylamide gels.f of theFederationofEuropeanBiochemical Societies.All rights reserved.
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A549 cells are ﬁxed in 3.7% paraformaldehyde and washed two
times with PBS. The cells are blocked and permealized with PBS con-
taining 1% BSA and 0.1% Triton X-100, and then incubated with anti-
ADAMTS1 antibody for A549 cells for 1 h. After washing, the cells
are resuspended in 500 ll PBS for analysis by a FACScalibur ﬂow
cytometry system.
2.4. RT–PCR
Total RNA was isolated from A549 cells using TrizolTM Reagent
(Life Technology). Reverse transcription reaction was performed using
2 lg of total RNA and reverse transcribed into cDNA using oligo dT
primer, then ampliﬁed 30 cycles using oligonucleotide primers derived
from published ADAMTS1 or b-actin sequence, including 5 0-CAG-
CCCAAGGTTGTAGATGGTA-3 0 and 5 0-TTCACTTCGATG-
TTGGTGGCTC-3 0 (ADAMTS1), or 5 0-TGACGGGGTCACCCA-
CACTGTGCC CATCTA-3 0 and 5 0-CTAGAAGCATTTGCGGG-
GACGATGGAGGG-30 (b-actin). PCR was carried out at 94 C for
30 s, at 55 C for 30 s and 1 min at 70 C for 34 cycles. The PCR prod-
ucts were subjected to 1.5% agarose gel electrophoresis. QuantitativeFig. 1. TSA and SAHA induce ADAMTS1 mRNA and protein expression in
6, 12, 24 or 48 h (A) or treated with 0.5, 1 lM TSA or 3, 5 lM SAHA for 24
A549 cells were treated with 1 lM TSA or 3 lM SAHA for 6, 12, 24 or 48 h.
speciﬁc for ADAMTS1, HDAC6 and Actin. (D) A549 cells were treated w
permealized then subjected to ﬂow cytometry as described Section 2.data were obtained using a computing densitometer and ImageQuant
Software (Molecular Dynamics).
2.5. Transient transfection and luciferase activity assay
The vectors were transiently transfected into A549 cells with Arres-
tin transfection reagent. Brieﬂy, 1 lg of plasmid DNA and 5 lL trans-
fection reagents were mixed, and the transfection protocol was carried
out according to the manufacturers instructions (Promega). Six hour
after transfection, the cells were cultured in normal complete medium
for another 16 h. The transfected cells with or without HDAC inhibi-
tor treatment were subjected to luciferase assay. Luciferase activities
were normalized with the amount of protein in cell lysates.
2.6. DNA aﬃnity protein binding assay
DAPA assay were performed as described [21]. DNA probes con-
taining the sequences of GC boxes of the ADAMTS1 promoter were
obtained by PCR ampliﬁcation using the following pairs of primers la-
beled with biotin: [5 0-TTCTTACACCCCCAGAGTGACGA-3 0], [5 0-
TACATAGGAGCCCCT CCTTCC-3 0]. The nuclear extract (400 lg)
was precleared at 4 C for 1 h with 20 ll of the 4% streptavidin-coatedA549 cells. A549 cells were treated with 1 lMTSA or 5 lM SAHA for
h (B), and total RNA (2 lg) was used for RT-PCR as described. In (C),
Whole cell lysate was prepared and subjected to Western blot using Ab
ith 1 lM TSA or 5 lM SAHA for 24 or 48 h. Cells were ﬁxed and
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Precleared nuclear extract was incubated with 4 lg of biotinylated
DNA oligonucleotides and 20 ll of 4% streptavidin agarose beads with
50% slurry in 400 ll PBS at 4 C for overnight with shaking. Beads
were then collected by centrifugation at 2000 rpm for 2 min andFig. 2. HDAC6 is implicated in the silencing of ADAMTS1 in A549 cells. (A
5 lM SAHA, 1 lMOxa, 1 lM TSA or 1 mM VPA for 16 h were harvested th
1 lM MS275, 1 mM NaB or 1 mM VPA for 24 h. Cells were ﬁxed and perm
cells treated with 20 lM tubacin or niltubacin for 16 h, and the stable HDAC6
subjected to RT-PCR as described. The expression of HDAC6 in vector con
(D) The A549 cells were treated with 1 lM TSA, 5 lM SAHA or 20 lM tub
cytometry.washed with cold PBS three times. DNA/protein complexes bound
to the beads were eluted with 30 ll of Laemmli sample buﬀer. Nuclear
proteins were denatured in a dry bath at 95 C for 5 min and subjected
to SDS–PAGE. Western blot analysis probed with speciﬁc anti-SP1 or
anti-HDAC6 antibody was performed as described above.) The total RNA of A549 cell treated with 1 lM MS275, 1 mM NaB,
en subjected to RT-PCR (B) A549 cells were treated with 5 lM SAHA,
ealized then subjected to ﬂow cytometry. (C) The total RNA of A549
knockdown A549 cells as well as its vector control were harvested then
trol and HDAC6 knockdown cells were examined by western blotting.
acin for 24 h. Cells were ﬁxed and permealized then subjected to ﬂow
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ChIP analysis was performed as described [22]. Immunoprecipitated
DNA was puriﬁed and resuspended in H2O, and subjected to PCR. To
amplify regions of the ADAMTS1 promoter, PCR was performed with
the following pairs of primers: [5 0-AGCGGCCCCAGCAGTA-
CAAAGT-30], [5 0-TTCCAGCGAGTGCAAGAACCGG-3 0] PCR
products were then resolved by 1.5% agarose-ethidium bromide gel
electrophoresis and visualized by UV.Fig. 3. The GC boxes in the proximal ADAMTS1 promoter are
required for TSA and SAHA-induced ADAMTS1. In (A) and (B),
A549 cells were transfected with serial deleted or the GC boxes-
truncated ADAMTS1-Luc, then treated with TSA or SAHA for 24 h.
Luciferase activity was measured as described in Section 2. The results
were normalized to the protein concentration and expressed as the
means ± S.E., for three independent experiments performed in tripli-
cate.3. Results
3.1. TSA and SAHA induce ADAMTS1 expression in A549
cells
We ﬁrst examined the eﬀect of prototype HDAC inhibitors,
TSA and SAHA, on ADAMTS1 expression. The result
showed that TSA or SAHA increased the mRNA expression
of ADAMTS1 in a time- and dose-dependent manner
(Fig. 1A and B). The protein level of ADAMTS1 was also
examined by Western blotting and ﬂow cytometry. Upregula-
tion of ADAMTS1 protein in a time-dependent manner was
seen after treatment with TSA and SAHA (Fig. 1C and D).
These data suggested that epigenetic dysregulation is involved
in the silencing of ADAMTS1 in A549 cells and HDAC inhib-
itors could reactivate its expression.
3.2. HDAC6. is involved in the silencing of ADAMTS1 in A549
cells
We further examined the eﬀects of HDAC inhibitors with
diﬀerent spectrum on ADAMTS1 expression. Cells were ex-
posed to several HDAC inhibitors for 16 h and only the broad
spectrum HDACi, TSA and SAHA, were capable to induce
ADAMTS1 expression (Fig. 2A and B). TSA and SAHA are
capable of inhibiting class I, IIa, IIb and IV HDACs, but
MS275, VPA and NaB only inhibit members of class I and
IIa HDACs [3]. The class IIb and class IV HDACs may mainly
engage in ADAMTS1 regulation. Therefore, we treated A549
cells with tubacin, a speciﬁc inhibitor of HDAC6 which be-
longs to the class IIb HDAC, and found that tubacin but
not its inactive analog, niltubacin [18], induced ADAMTS1
expression (Fig. 2C and D). ADAMTS1 expression was also
higher in HDAC6 knockdown cells comparing to its vector
control (Fig. 2C). The expression of HDAC6 in knockdown
cells was conﬁrmed by immunoblot (Fig. 2C). These data
implied that HDAC6 is involved in the regulation of ADAM-
TS1 expression.
3.3. GC boxes are required for TSA- and SAHA-induced
ADAMTS1
There are several cis-elements on the ADAMTS1 promoter,
such as c-Ets, NF-1, C/EBP and GC boxes. Cells were trans-
fected with either 1186 bp, truncated 375 bp or 151 bp
ADAMTS1-Luc. The 151 bp ADAMTS1-Luc reporter was
found to be suﬃcient for the induction of ADAMTS1 pro-
moter activity in response to TSA and SAHA stimulation
(Fig. 3A and B), indicating that the inducible region is within
the 151 promoter. There are three GC boxes on the ADAM-
TS1 promoter. The reporter truncated with diﬀerent GC boxes
was examined. Mutation of GC-II and GC-III was found to
disrupt the basal promoter activity, their role in TSA-induced
promoter activity remained to be identiﬁed. However, trunca-
tion of GC-I, which possessed unaﬀected basal promoter activ-
ity, signiﬁcantly attenuated the TSA-induced promoter activity(Fig. 3C), suggesting that GC-I is essential for HDACi-
induced ADAMTS1 expression.
3.4. TSA disturbed the binding of HDAC6 and SP1 to
ADAMTS1 promoter
Since HDAC6 and GC boxes were implicated in HDACi-
induced ADAMTS1 expression, the binding of HDAC6 and
SP1/3 to its promoter after TSA treatment was examined by
DAPA and ChIP assays. The decreased binding of SP1 to
the ADAMTS1 promoter was demonstrated, although par-
tially recovery was seen at 8 h treatment by DAPA assay
(Fig. 4A and B). However, ChIP assay showed the invariant
binding of SP3 (Fig. 4A and B). The promoter binding was
highly correlated with the nuclear amount of SP1, suggesting
that HDACi may regulate the localization of SP1 to control
its availability for ADAMTS1 promoter. HDAC6 was also re-
moved from ADAMTS1 promoter (Fig. 4A and B) and CBP
was recruited upon treatment with HDACi (Fig. 4B). These
data imply that the inhibitory role of SP1 and HDAC6 for
the regulation of ADAMTS1 is relieved by the inhibition of
HDAC, leading to the reactivation of ADAMTS1.4. Discussion
In this study, we showed that TSA and SAHA induced the
expression of angioinhibitory ADAMTS1. The upregulation
of ADAMTS1 in HDAC6 knockdown A549 cells was also
Fig. 4. TSA decreased the binding of SP1 and HDAC6 to ADAMTS1 promoter. (A) A549 cells were treated with 1 lM TSA for various times, then
nuclear extracts were prepared. Nuclear extracts were mixed with biotinylated ADAMTS1 promoter probe containing GC boxes I–III, then Sp1,
HDAC6, or HDAC2 were detected by Western blotting. (B) The binding of SP1/3, HDAC6 and CBP on ADAMTS1 proximal promoter was
assessed by ChIP assay. A549 cells were treated with TSA for various times, ChIP assays were performed using antibody speciﬁc for SP1/3, HDAC6
and CBP or normal rabbit IgG (Control) to assay the precipitated ADAMTS1 promoter as described in Section 2. 1.5% of total chromatin was
assayed to verify equal loading (Input).
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acin, increased the ADAMTS1 expression as well. By reporter
assay, the GC boxes in the proximal region of ADAMTS1 pro-
moter were demonstrated to be essential for the TSA-induced
promoter activity. Moreover, HDAC inhibition disturbed the
binding of SP1 and HDAC6 from the ADAMTS1 promoter,
thereby leading to the induction of ADAMTS1.
The angioinhibitory properties of HDAC inhibitors have
been reported to downregulate proangiogenic genes, leading
to their inhibition of neo-vascularization. For example, mostHDACi are able to reduce the expression of vascular endothe-
lial growth factor (VEGF), basic ﬁbroblast growth factor
(bFGF), hypoxia-inducible factor-1a (HIF1a), angiopoietin,
tunica intima endothelial kinase 2 (TIE2) and endothelial nitric
oxide synthase (eNOS) [23–28]. Also, HDACi have been re-
ported to downregulate the expression of chemokine (C-X-C
motif) receptor 4 (CXCR4), which is essential for the guidance
of circulating endothelial cells to sites of angiogenesis [28,29].
Moreover, HDACi have been shown to suppress endothelial
progenitor cell diﬀerentiation [28]. However, the eﬀects of
4064 C.-W. Chou, C.-C. Chen / FEBS Letters 582 (2008) 4059–4065HDACi on transformed cells and angioinhibitory genes are
largely unexplored. In this study, we demonstrated that the
HDACi, TSA and SAHA, upregulated the angioinhibitory
gene, ADAMTS1, in transformed A549 cells. These data sug-
gested that HDACi not only reduce the pro-angiogenesis genes
but also induce the angioinhibitory gene. ADAMTS1 is the
prototype of the ADAMTS family proteins. It has been re-
ported to bind to VEGF165 and inhibit its binding to
VEGF-receptor 2 on endothelial cells [9,16]. The antiangio-
genic potency of ADAMTS1 has been described to be greater
than that of either thrombospondin 1 or endostatin at the same
molar ratio [12]. The binding ability of ADAMTS1 to
VEGF165 has been assigned in its thrombospondin motifs
[16]. In addition to VEGF165 sequestration, ADAMTS1 also
mediates the release of polypeptides from the trimeric structure
of both TSP1 and 2 which could generate a pool of antiangio-
genic fragments from matrix-bound thrombospondin [15].
Overexpression of the C-terminal region of ADAMTS1, con-
sisting of TSP type I motifs and the spacer region, suppressed
Chinese hamster ovary (CHO) tumor growth and metastasis
[30].
Although ADAMTS1 has been reported to be silenced in
NSCLC [17], approaches to its reactivation in NSCLC has
never been reported. In this study, we demonstrated that
HDACi, the most promising anticancer agent, was capable
of inducing ADAMTS1 in A549 cells. This induction depends
on the regulation of HDAC6 and SP1. It has been reported
that the C/EBPb, NF-1-like, SP1/3 binding sites are essential
for the ADAMTS1 induction by LH and progesterone recep-
tor in granulosa cell [20]. We showed that the proximal GC-I
was required for the HDACi-induced expression of ADAM-
TS1, suggesting the involvement of SP1. TSA has been demon-
strated to decrease the binding of HDAC1 to the MT-1
promoter [31]. In pancreatic adenocarcinoma cell lines, TSA
disrupts the association between HDAC1 and SP1, and de-
creases the binding of HDAC1 to TGFBR2 promoter [32].
In our previous study, we demonstrated that statin and TSA
released HDAC1/2 from the p21 promoter [33]. There are also
reports demonstrating that SAHA releases HDAC from an
Sp1 site [34]. These ﬁndings implied that HDAC inhibition
may alter the composition of ADAMTS1 promoter-associated
proteins. By DAPA and ChIP assays, we demonstrated that
SP1 was dispersed from ADAMTS1 promoter after TSA treat-
ment, suggesting an inhibitory role of SP1 in ADAMTS1 reg-
ulation. The promoter binding of SP1 was highly correlated
with its nuclear amount, suggesting HDACi may regulate the
SP1 localization to control its availability for ADAMTS1 pro-
moter. Meanwhile, HDAC6 was also removed from the
ADAMTS1 promoter, while CBP was recruited. This data cor-
respond with the previous ﬁnding about the involvement of
HDAC6 in ADAMTS1 induction, suggesting that HDAC6 is
probably responsible for the epigenetic silence of ADAMTS1
in NSCLC. Overall, our ﬁndings oﬀered a novel angioinhibito-
ry eﬀect of HDAC inhibitors and may be helpful for the devel-
opment of NSCLC therapy.
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